Bexicaserin clinical trials
Also written LP352.
How each study uses bexicaserin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bexicaserin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test bexicaserin, phase 3 first.
- Dec 2026A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Phase 3 · Longboard Pharmaceuticals
- Nov 2027A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)Phase 3 · Longboard Pharmaceuticals
Studies
Open first, then newest update. How each study uses bexicaserin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)Enrolling by invitationPhase 3Longboard PharmaceuticalsNCT06908226Written as LP352
- A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Active, not recruitingPhase 3Longboard PharmaceuticalsNCT06660394Written as LP352
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)Active, not recruitingPhase 3Longboard PharmaceuticalsNCT06719141Written as LP352
- Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic EncephalopathyCompletedPhase 2Longboard PharmaceuticalsNCT05626634Written as LP352, bexicaserin
- Study to Investigate LP352 in Subjects With Developmental and Epileptic EncephalopathiesCompletedPhase 1/2Longboard PharmaceuticalsNCT05364021Written as LP352
Codes
What other systems call bexicaserin · ClinicalTrials.gg INT017775
- UNII (FDA) R8XR1D6SCBBEXICASERINOne source FDA
- NCI Thesaurus C203219BexicaserinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R8XR1D6SCB | BEXICASERIN | One source FDA |
| NCI Thesaurus | C203219 | Bexicaserin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.